Ítem
Acceso Abierto

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus

Mostrar el registro sencillo de la publicación
dc.creatorKheir, Joseph M
dc.creatorGuthridge, Carla J
dc.creatorJohnston, Jonathon R
dc.creatorAdams, Lucas J
dc.creatorRasmussen, Astrid
dc.creatorGross, Timothy F
dc.creatorMunroe, Melissa E
dc.creatorBourn, Rebecka L
dc.creatorSivils, Kathy L.
dc.creatorGuthridge, Joel M.
dc.creatorWeisman, Michael H.
dc.creatorWallace, Daniel J.
dc.creatorAnaya, Juan-Manuel
dc.creatorRojas-Villarraga, Adriana
dc.creatorJarvis, James N
dc.creatorHarley, John B.
dc.creatorJames, Judith A.
dc.creator.googleKheir, Joseph M
dc.creator.googleGuthridge, Carla J
dc.creator.googleJohnston, Jonathon R
dc.creator.googleAdams, Lucas J
dc.creator.googleRasmussen, Astrid
dc.creator.googleGross, Timothy F
dc.creator.googleMunroe, Melissa E
dc.creator.googleBourn, Rebecka L
dc.creator.googleSivils, Kathy L.
dc.creator.googleGuthridge, Joel M.
dc.creator.googleWeisman, Michael H.
dc.creator.googleWallace, Daniel J.
dc.creator.googleAnaya, Juan-Manuel
dc.creator.googleRojas Villarraga, Adriana
dc.creator.googleJarvis, James N
dc.creator.googleHarley, John B.
dc.creator.googleJames, Judith A.
dc.date.accessioned2019-02-20T20:59:09Z
dc.date.available2019-02-20T20:59:09Z
dc.date.created2018
dc.date.issued2018
dc.description.abstractObjective: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with varied morbidity and mortality. We assessed clinical presentations, autoantibody specificities and therapeutic interventions in Native American (NA) patients with SLE. Methods: Patients with SLE meeting 1997 American College of Rheumatology classification criteria (n=3148) were enrolled between 1992 and 2010 in the multiethnic, cross-sectional Lupus Family Registry and Repository. Clinical, demographic and therapeutic information were extracted from medical records using a standardised form and formalised training. Autoantibodies were assessed by indirect immunofluorescence (antinuclear antibodies (ANA) and antidouble-stranded DNA), precipitin (ENA) and ELISA (IgG and IgM anticardiolipins). Results: NA patients met SLE classification at a younger age (29.89±12.3 years) than European Americans (EA; 32.02±12.87, P=0.0157) and a similar age to African-Americans (AAs) and Hispanics (HIS). More NA patients had concurrent rheumatic diseases or symptoms, such as Raynaud's phenomenon, interstitial lung disease, Sjögren's syndrome and systemic sclerosis. Compared with EAs, NAs were more likely to have high-titre ANA (≥1:3240; P<0.0001) and had more SLE-associated autoantibodies. Autoantibodies with unknown specificities were more common in NAs (41%) compared with other racial/ethnic groups in this collection (AA: 24%, P=0.0006; EA: 17%, P<0.0001; HIS: 23%, P=0.0050). Fewer NA patients used hydroxychloroquine (68%) compared with others (AA: 74%, P=0.0308; EA: 79%, P=0.0001, HIS: 77%, P=0.0173); this was influenced by lower hydroxychloroquine use in NA patients from Latin America (32%). NA patients had higher rates of methotrexate use (28%) compared with AA (18%, P=0.0006) and HIS patients (14%, P=0.0003), higher azathioprine use (38%) compared with EA patients (30%, P=0.0105) and higher mycophenolate mofetil use (26%) compared with EA (17%, P=0.0012) and HIS patients (11%, P<0.0001). Conclusions: NA patients are diagnosed with SLE earlier in life and present worse concurrent rheumatic disease symptoms than EA patients. NA patients also are more likely to have expanded autoantibody profiles and precipitins of unknown specificities. © 2018 Article author(s).eng
dc.format.mimetypeapplication/pdf
dc.identifier.doi10.1136/lupus-2017-000247
dc.identifier.issn2053-8790
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/19121
dc.language.isoengspa
dc.relation.citationTitleLupus Science and Medicine
dc.relation.citationVolumeVol. 5
dc.relation.ispartofLupus Science and Medicine, ISSN:2053-8790, Vol. 5 (2018)spa
dc.relation.urihttps://lupus.bmj.com/content/5/1/e000247spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.bibliographicCitationManuel, F., Ugarte-Gil, G.J.P.-E., Alarcon, G.S., Epidemiology (2016) Systemic Lupus Erythematosusspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectAntinuclear Antibodyspa
dc.subjectAutoantibodyspa
dc.subjectCardiolipin Antibodyspa
dc.subjectDouble Stranded Dna Antibodyspa
dc.subjectHydroxychloroquinespa
dc.subjectImmunoglobulin G Antibodyspa
dc.subjectImmunoglobulin M Antibodyspa
dc.subjectMethotrexatespa
dc.subjectMycophenolate Mofetilspa
dc.subjectPrecipitinspa
dc.subjectAfrican Americanspa
dc.subjectAmerican Indianspa
dc.subjectAntibody Specificityspa
dc.subjectAntibody Titerspa
dc.subjectClinical Featurespa
dc.subjectControlled Studyspa
dc.subjectDrug Usespa
dc.subjectEnzyme Linked Immunosorbent Assayspa
dc.subjectEthnic Differencespa
dc.subjectEuropean Americanspa
dc.subjectHispanicspa
dc.subjectHumanspa
dc.subjectImmunofluorescencespa
dc.subjectInterstitial Lung Diseasespa
dc.subjectMajor Clinical Studyspa
dc.subjectMalespa
dc.subjectMouth Ulcerspa
dc.subjectPhotosensitivityspa
dc.subjectPriority Journalspa
dc.subjectRace Differencespa
dc.subjectRaynaud Phenomenonspa
dc.subjectSjoegren Syndromespa
dc.subjectSystemic Lupus Erythematosusspa
dc.subjectSystemic Sclerosisspa
dc.subject.ddcEnfermedadesspa
dc.subject.keywordAdultspa
dc.subject.keywordArticlespa
dc.subject.keywordFemalespa
dc.subject.lembAnticuerposspa
dc.subject.lembLupus eritematosospa
dc.titleUnique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosusspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
117.pdf
Tamaño:
523.51 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos